Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonathan N. Le, Jordan O. Gasho, Olivia Peony, Asneh Singh, Katrina D. Silos, Sungjin Kim, Anthony T. Nguyen, Mitchell Kamrava, Amin Mirhadi, Behrooz Hakimian, Karen L. Reckamp, Kamya Sankar, Raymond H. Mak, Andriana P. Nikolova, Katelyn M. Atkins
Formato: Artículo
Lenguaje:English
Publicado: Frontiers Media S.A. 2024-12-01
Colección:Frontiers in Cardiovascular Medicine
Materias:
osimertinib
lung cancer
cardiac toxicity
echocardiogram
EGFR
Acceso en línea:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Ejemplares similares